Day: October 7, 2021
Press release
Disposal of two non-strategic assetsSale of a logistics warehouse and a small vacant stand-alone property for a total of €4.9 million (excluding transfer taxes)Paris, 7 October 2021: MRM (Euronext code ISIN FR0000060196), a real estate investment company specialising in retail property, today announced the sale of two properties representing 10,200 sqm altogether for a total €4.9 million (excluding transfer taxes), 13% above the properties’ valuations as at end-June 2021.
These disposals concern two non-strategic assets in the Gamm Vert sub-portfolio acquired in 2007. They are:A 8,600 sqm warehouse in Mer (Loir-et-Cher), currently let to Gamm Vert. The warehouse has been sold to a foreign investor specialising in industrial and logistics developments.
A 1,600 sqm stand-alone property in Salbris (Loir-et-Cher)...
SIKA DEMONSTRATES PROOF OF CONCEPT OF CONCRETE RECYCLING – STRATEGIC TARGETS FOR 2023 CONFIRMED AT CAPITAL MARKETS DAY IN ZURICH
Written by Customer Service on . Posted in Public Companies.
SIKA DEMONSTRATES PROOF OF CONCEPT OF CONCRETE RECYCLING – STRATEGIC TARGETS FOR 2023 CONFIRMED AT CAPITAL MARKETS DAY IN ZURICH
At the Sika Capital Markets Day 2021 being held in Zurich today, CEO Thomas Hasler confirms the strategic targets 2023. Under the motto: “Sika as Enabler for a Sustainable Construction Industry”, members of Group Management and Sika experts demonstrate the groundbreaking Sika concrete recycling process at a test facility in Zurich. The new reCO2ver concept can be considered a breakthrough in concrete recycling and has the potential to significantly contribute to a more sustainable and circular economy. Furthermore, Sika demonstrates how to further drive the decarbonization of the construction industry, and how innovations meet the challenges of tomorrow.
Thomas Hasler, CEO of Sika: “Our company...
Elis: Acquisition of Blesk InCare’s Textile activity in Russia
Written by Customer Service on . Posted in Mergers And Acquisitions.
Acquisition of Blesk InCare’s Textile activity in Russia
Saint-Cloud, October 7, 2021 – Elis, an international multi-service provider, offering textile, hygiene, and facility services solutions, which is present in Europe and Latin America, today announces the signing of an agreement to acquire 100% of Blesk InCare’s Textile activity. The closing of the transaction is subject to customary regulatory conditions and is expected to occur by the end of 2021.
Elis has been present in Russia since 2017 through the acquisition of Berendsen. After the acquisition of Blesk InCare’s Mats activity in 2019, the Group continues its development strategy to take over the Flat Linen and Workwear business of the Russian group.
2021 revenue is expected at 700m Russian rubles (c. €8 million), with Flat Linen and Workwear contributing c. 60% and 40% respectively....
FreshBooks Announces Acquisition of Germany-based FastBill, Accelerating Global Expansion
Written by Customer Service on . Posted in Mergers And Acquisitions.
Toronto, Canada, Oct. 07, 2021 (GLOBE NEWSWIRE) — FreshBooks, a leading cloud accounting software provider with paying customers in 160+ countries, announced today the acquisition of FastBill, one of Germany’s leading cloud accounting and invoicing software solutions. Founded in 2011 in Frankfurt, Germany, FastBill helps self-employed professionals, small businesses, and startups maintain better control of their finances through electronic invoice management, reporting, and access to tax advisory services. The terms of the transaction have not been disclosed.
“With its complementary mission and culture, we are extremely excited about our acquisition of FastBill and how it strengthens our global expansion plans,” said Don Epperson, CEO of FreshBooks. “This acquisition, paired with FreshBooks’ leadership in streamlining and...
Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering
Written by Customer Service on . Posted in Public Companies.
BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to additional 2,100,000 ordinary shares and/or additional warrants to purchase up to 2,100,000 ordinary shares, at the public offering price per share and per warrant, respectively, less the underwriting...
Capgemini Press Release// Capgemini World Payments Report 2021
Written by Customer Service on . Posted in Public Companies.
Capgemini Press Contacts:
WE Communications for CapgeminiMary Sacchi (North America)Tel.: +1 (212) 551 4818
E-mail: msacchi@we-worldwide.com
Bartu Sezer (EMEA)WE Communications for Capgemini Tel.: +44 (0)20 7632 3861E-mail: bsezer@we-worldwide.com
As use of alternative payments is skyrocketing, banks must urgently embrace the next generation of payments to stay in the race: Capgemini’s World Payments Report 2021
The report found that by 2025, instant payments and e-money payments will account for more than 25% of global non-cash transactions, up from 14.5% in 2020.
Paris, October 7, 2021 – Payments are entering a new experience-driven era (Payments 4.X1), ushered in by an accelerated transformation timeline due to COVID-19 and the growing digital appetite of customers, according to the World Payments Report 2021 published today by Capgemini....
Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart Failure Selected as Late Breaking Presentation at American Heart Association Annual Meeting
Written by Customer Service on . Posted in Public Companies.
NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association (NYHA) class II and class III chronic heart failure (CHF) with low ejection fraction (HFrEF) have been selected through peer review as a late breaking presentation at the American Heart Association (AHA) annual meeting occurring November 13th– 15th. The featured session is titled ‘Building on the Foundations of Treatment: Advances in Heart Failure Therapy’.
The trial’s co-principal investigator Dr Emerson Perin, Medical Director of Texas Heart Institute, and Clinical Professor, Baylor College of Medicine, will give the presentation...